“Malignant tumors in kidney cells are one of the most insidious types of cancer worldwide. They are often only diagnosed at a late stage and have a significant unmet medical need”, says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare,
Journalists may submit their applications by March 1, 2011, to the Kidney Cancer Association – Project Office,
Members of the jury are up to four representatives from journalistic organizations, one urologist and one oncologist, one member of the Kidney Cancer Association as well as one non-voting representative from Bayer HealthCare. The award will be presented in
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry and is based in
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.
Helmut Schäfers, Phone: +49 214 30-5830
E-mail: [email protected]
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.